MDCX · Medicus Pharma Ltd.
$0.16
+0.00 (+0.74%)
At close · Sep 11
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed Aug 12, 2026
Market Cap
$10.27M
Shares
63.18M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.16
Open$0.16
Day$0.15–0.16
52W close$0.16–2.80
Avg vol 30d6.7M
Short int3.4M · 5.3% float · 2.6d
Short vol59%
DataNov 2024–Sep 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$56.66M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+285.4%
Year over year · more shares
Price change (1Y)
-92.8%
Trailing year
Short interest
5.3%
Latest settlement · 2.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−78%
below
Price vs 50-day avg
−47%
below
RSI (14)
27
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−54%
trailing
6-month return
−68%
trailing
YTD return
−89%
this year
Relative strength
−86%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.31% of float · ▲ +20.3% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 1-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
129%
annualized · 1-yr
Max drawdown
−94%
past year
ATR
16.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−78%
Bearish
Price vs 50-day avg
−47%
Bearish
RSI (14)
27
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.31% of float · ▲ +20.3% MoM · 2.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $3
vs 200-day avg -78%
vs 50-day avg -47%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDCX
this stock
Medicus Pharma Ltd.
|
$10.27M | -89.4% | — | — | 5.3% |
|
LLY
ELI LILLY & Co
|
$1.05T | +3.8% | +44.7% | 37.4 | 0.8% |
|
JNJ
Johnson & Johnson
|
$640.02B | +28.3% | +6.0% | 30.9 | 0.9% |
|
ABBV
AbbVie Inc.
|
$454.36B | +12.5% | +8.6% | 72.6 | 1.1% |
|
MRK
Merck & Co., Inc.
|
$355.10B | +36.7% | +1.3% | 115.1 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDCX | -4.9% | -54.1% | -68.1% | -37.9% | -89.4% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -3.8% | -52.3% | -85.9% | -37.6% | -101.5% |